Cartesian Therapeutics, Inc. (RNAC) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
RNAC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RNAC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | -3099.9% | -4658.6% |
| 2024 | 100.0% | -112.8% | -199.0% |
| 2023 | 100.0% | -332.3% | -844.9% |
| 2022 | 98.2% | 13.1% | 31.9% |
| 2021 | 100.0% | -5.4% | -30.2% |
Download Data
Export RNAC earnings history in CSV or JSON format
Free sign-in required to download data
Cartesian Therapeutics, Inc. (RNAC) Earnings Overview
As of May 8, 2026, Cartesian Therapeutics, Inc. (RNAC) reported trailing twelve-month net income of -$152M, reflecting -52.6% year-over-year growth. The company earned $-5.65 per diluted share over the past four quarters, with a net profit margin of -4658.6%.
Looking at the long-term picture, RNAC's historical earnings data spans multiple years. The company achieved its highest annual net income of $35M in fiscal 2022.
Cartesian Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), IMVT (-$464M net income), ARQT (-$2M net income, -4.3% margin), RNAC has room to improve margins relative to the peer group. Compare RNAC vs KYMR →
RNAC Earnings vs Peers
Earnings metrics vs comparable public companies
RNAC Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$130M | -68.3% | -$87M | $-5.02 | -4658.6% | -3099.9% |
| 2024 | -$77M | +64.8% | -$44M | $-3.29 | -199.0% | -112.8% |
| 2023 | -$220M | -721.0% | -$86M | $-49.76 | -844.9% | -332.3% |
| 2022 | $35M | +237.7% | $15M | $3.00 | 31.9% | 13.1% |
| 2021 | -$26M | +62.7% | -$5M | $-6.60 | -30.2% | -5.4% |
| 2020 | -$69M | -24.4% | -$57M | $-20.42 | -415.0% | -342.4% |
| 2019 | -$55M | +15.3% | -$52M | $-36.46 | -829.0% | -785.6% |
| 2018 | -$65M | -0.0% | -$65M | $-87.55 | -7235.4% | -7200.7% |
| 2017 | -$65M | -80.4% | -$64M | $-95.94 | -31556.0% | -30813.5% |
| 2016 | -$36M | -43.8% | -$35M | $-103.52 | -448.0% | -428.9% |
See RNAC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNAC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RNAC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRNAC — Frequently Asked Questions
Quick answers to the most common questions about buying RNAC stock.
Is RNAC growing earnings?
RNAC EPS fell to $-5.65, with earnings declining -52.6%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-152M.
What are RNAC's profit margins?
Cartesian Therapeutics, Inc. net margin is -4658.6%, with operating margin at -3099.9%. Below-average margins reflect competitive or cost pressures.
How consistent are RNAC's earnings?
RNAC earnings data spans 2014-2025. The declining earnings trend is -52.6% YoY. Historical data enables comparison across business cycles.